Treatment of recurrent depression

@article{Fava2006TreatmentOR,
  title={Treatment of recurrent depression},
  author={Giovanni Andrea Fava and Seung K. Park and Nicoletta Sonino},
  journal={Expert Review of Neurotherapeutics},
  year={2006},
  volume={6},
  pages={1735 - 1740}
}
Approximately eight out of ten people experiencing a major depressive episode will have one or more further episodes during their lifetime: a recurrent major depressive disorder. Prolongation or lifelong pharmacotherapy has emerged as the main therapeutic tool for preventing relapse in depression. However, outcome after discontinuation of antidepressants does not seem to be affected by the duration of their administration. Loss of clinical effects, despite adequate compliance, has also emerged… Expand
Heart Rate Variability Biofeedback Stress Relief Program for Depression*. A Replicated Single-Subject Design
TLDR
The intervention had more clinical impact on resilience-related outcome measures than on symptoms, and the small sample size does not permit generalization of the results. Expand
The Role of Early Life Stress in HPA Axis and Depression
TLDR
This review examines the emerging literature on the relationship between stress, hypothalamic-pituitary-adrenal (HPA) axis function, and depression and the role of early life stress as an important risk factor for HPA axis dysregulation and suggests that this dysregulation of the HPAaxis is partially attributable to an imbalance between glucocorticoid and mineralocortioid receptors. Expand
Towards a neuroimaging biomarker of depression vulnerability
Major depressive disorder (MDD) is a pervasive and debilitating illness, with a recurrent course and chronic prognosis. Although effective treatments for MDD exist, there is a pressing need toExpand
Early life stress, HPA axis, and depression
evidence from various studies suggests a preeminent role for early adverse experiences in the development of psychopathology, especially depression. The most recent studies reviewed herein suggestExpand
Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists?
TLDR
Convergent preclinical and clinical evidence has suggested that liraglutide may improve objective measures of cognitive function in adults with mood disorders and the safety and availability of GLP‐1R agonists indicate that they are promising candidates for repurposing, and that they may be viable therapeutic options for mood disorders. Expand
Association of fish and long-chain n-3 polyunsaturated fatty acid intakes with the occurrence of depressive episodes in middle-aged French men and women.
TLDR
It is suggested that a usual intake of fatty fish or long-chain n-3 PUFA may decrease the risk of recurrent depression in non-smokers. Expand
Should women be screened for postnatal depression? Exploring the effects of undiagnosed maternal mental health problems on child development.
TLDR
Higher levels of persistent depression were identified in women who were diagnosed and treated for depression and this persistency was found to have an additive effect on child outcomes, with longer-term maternal mental health problems much more strongly associated with child outcomes than postnatal depression alone. Expand
A lifespan view of anxiety disorders
TLDR
Data on anxiety disorders as they appear in older adults, as compared with earlier in life is presented and optimal management of anxiety disorders across the lifespan is described, in “eight simple steps” for practitioners. Expand
Effectiveness in mental health: a review and rethink of some basic assumptions and common practices
Despite recent advances in mental health research and treatment, prevalence rates remain high and stable in many countries around the globe. Current efforts to address the problem largely focus onExpand
Integrating mental health and primary care.
TLDR
Effective integration of mental health care into primary care requires systematic and pragmatic change that builds on the strengths of both mental health and primary care. Expand
...
1
2
...

References

SHOWING 1-10 OF 62 REFERENCES
Treatment of Recurrent Depression
TLDR
Despite an impressive amount of research into the treatment of depression, there is still a paucity of studies addressing the specific problems that prevention of recurrent depression entails and it is important to discuss with the patient the various therapeutic options and to adapt strategies to the specific needs of patients. Expand
Treatment Approaches to Major Depressive Disorder Relapse
TLDR
The results generally support increasing dose as a first-line treatment strategy for a patient who has relapsed while taking a previously effective dose of an antidepressant. Expand
Treatment approaches to major depressive disorder relapse. Part 1: dose increase.
TLDR
The patients relapsing after initially responding to fluoxetine can benefit from an increase in fluoxettine dose, and results generally support increasing dose as a first-line treatment strategy for a patient who has relapsed while taking a previously effective dose of an antidepressant. Expand
Treatment approaches to major depressive disorder relapse. Part 2: reinitiation of antidepressant treatment.
TLDR
The results challenge the view that the efficacy of an agent prematurely discontinued is diminished when such an agent is restarted and generally support reinitiation of the same antidepressant as a 'first-line' treatment strategy in patients who relapsed after stopping a previously effective antidepressant. Expand
Treatment Approaches to Major Depressive Disorder Relapse
TLDR
The results challenge the view that the efficacy of an agent prematurely discontinued is diminished when such an agent is restarted and generally support reinitiation of the same antidepressant as a ‘first-line’ treatment strategy in patients who relapsed after stopping a previously effective antidepressant. Expand
Six-year outcome of cognitive behavior therapy for prevention of recurrent depression.
TLDR
Cognitive behavior treatment of residual symptoms was found to yield a significantly lower relapse rate than clinical management in recurrent depression at a 2-year follow-up, suggesting that the sequential use of cognitive behavior treatment after pharmacotherapy may improve the long-term outcome in recurrent depressed. Expand
Tolerance in Antidepressant Treatment
TLDR
Observations are provided from their long-term collaborative study of outpatients with moderately severe, recurrent unipolar depression who relapsed during longterm treatment with (B)-fluoxetine, extending previous observations that increasing fluoxettine doses can rescue some late failures. Expand
Discontinuing Antidepressant Treatment in Major Depression
TLDR
Compared with patients whose antidepressants were discontinued, those with continued treatment showed much lower relapse rates, and differences in relapses off versus on antidepressants fell markedly with longer follow‐up, but gradual discontinuation (dose‐tapering or use of long‐acting agents) did not yield lower relapse rate. Expand
Prevention of relapse following cognitive therapy vs medications in moderate to severe depression.
TLDR
Cognitive therapy has an enduring effect that extends beyond the end of treatment and seems to be as effective as keeping patients on medication. Expand
Can long-term treatment with antidepressant drugs worsen the course of depression?
  • G. Fava
  • Psychology, Medicine
  • The Journal of clinical psychiatry
  • 2003
TLDR
The possibility that antidepressant drugs may worsen the course of depression needs to be tested, even though its scientific exploration is likely to encounter considerable methodological and ideological difficulties. Expand
...
1
2
3
4
5
...